Biopreservation Market: Market Size & Forecast 2026

Biopreservation involves the storage and preservation of biological specimens, including stem cells, cord blood, tissues, DNA, and RNA, using specialized equipment, cryogenic media, and controlled-temperature systems. The market is valued at approximately $4.41 billion in 2025, with estimates across commercial research firms generally ranging between $4.1 billion and $4.7 billion for the base year. The market encompasses three primary product categories: consumables (cryogenic media, vials, bags), equipment (freezers, refrigerators, racks), and services (biobanking and storage infrastructure).

• •Market encompasses equipment, consumables, and services for cryogenic and controlled-temperature storage of biological samples
• •2025 base-year estimates across sources range from approximately $4.11 billion to $4.71 billion
• •Growth rates cited across research firms for the 2025-2030 period range from approximately 8% to 25.35% CAGR

The expansion of biobanks, both government-funded and commercial, is a major catalyst, as large-scale sample repositories require robust, long-term preservation infrastructure. Rising adoption of cell-based and gene therapies, particularly CAR-T treatments and stem cell therapies, demands specialized cryopreservation solutions that maintain cell viability through manufacturing chains. Increased investment in personalized medicine, regenerative medicine research, and drug discovery pipelines further fuels demand for reliable biopreservation systems and compatible media formulations.

• •Growing global network of biobanks supporting genomic research, clinical trials, and disease registries
• •Rising number of FDA-approved and late-stage cell and gene therapies requiring specialized preservation protocols
• •Increasing life sciences R&D spending and expansion of personalized medicine programs globally

By product, the market is commonly segmented into consumables, equipment, and services, with consumables, particularly cryoprotective agents and media, representing the largest revenue share due to recurring demand. By application, key segments include human biopsy samples, stem cells, cord blood, eggs, sperm, and other biological specimens. North America currently leads the global market, driven by a high concentration of biopharmaceutical companies, advanced biobanking infrastructure, and regulatory support for regenerative medicine research.

• •North America holds the largest regional share, supported by a dense biopharma ecosystem and extensive biobank networks
• •Europe and the Asia-Pacific region are significant and growing markets, with Asia-Pacific expanding rapidly due to healthcare investment growth
• •Consumables and cryogenic media typically represent the largest product segment due to ongoing replenishment demand

What are the recent trends and outlook?

Automation and digitalization of biobanking operations, including AI-driven sample tracking and inventory management, are emerging as key differentiators as biobanks scale to handle millions of samples. GMP-compliant biopreservation solutions are gaining prominence as cell and gene therapy manufacturing moves toward standardized, regulated production environments. Emerging markets in Asia and Latin America are expected to outpace developed regions in growth rate terms, driven by healthcare infrastructure expansion, while increasing regulatory harmonization around biologic sample handling is likely to shape product development and compliance requirements industry-wide.

• •Automation, IoT-connected freezers, and AI-based inventory management are transforming biobanking operations at scale
• •Growing emphasis on GMP-grade cryopreservation media and allogeneic cell banking infrastructure
• •Asia-Pacific and Latin America projected as the fastest-growing regional markets through the decade